Press Release

February 19, 2014
Verastem to Host Conference Call on March 6th to Discuss Year-End 2013 Financial Results and Recent Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will host a conference call on Thursday, March 6, 2014 at 8:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013.

The call can be accessed by dialing (866) 953-6857 (U.S. and Canada) or (617) 399-3481 (international), and entering passcode 51092744. The teleconference replay will be available for one week by dialing (888) 286-8010 (U.S. and Canada) and (617) 801-6888 (international). Replay Passcode 64460610 is required for playback.

To access the live audio webcast, visit the investors section of the Verastem website at www.verastem.com. The webcast will also be recorded and available for replay on the company’s website for 90 days.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com